|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Absolute quantification of FGFR1 from formalin fixed paraffin embedded (FFPE) tissue of laryngeal SCCa was examined in this retrospective study.
|
29351293 |
2018 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck.
|
29022097 |
2018 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that FGFR1 gene amplification is a frequent alteration in SCC of the lung and appears not to be a negative but rather a favorable prognostic marker for women and particularly for patients with advanced SCC of the lung (stage III-IV).
|
29270870 |
2018 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
All 8 patients with squamous cell carcinoma had multiple variants identified (range, 1-20; median, 6), including FGFR1 amplification and ERBB2 (HER2) amplification.
|
29807856 |
2018 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Using samples from 122 patients, we established 41 NSCLC PDXs [30 adenocarcinoma (AD), 11 squamous cell carcinoma (SQ)], among which the following driver mutation were observed: 13 EGFR-mutant, 4 ALK-rearrangement, 1 ROS1-rearrangement, 1 PIK3CA-mutant, 1 FGFR1-amplification, and 2 KRAS-mutant.
|
30268457 |
2018 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The lung cancer subtypes share some genetic variations such as the dysfunction of tumor suppressor gene TP53, and also harbor specific variations of their own such as MET in ADC, FGFR1 and FGFR3 in SCC and MYC in SCLC.
|
27845189 |
2017 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGFR1 amplification is more frequent in SCCs than in ADCs.
|
27901003 |
2016 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with pretreated advanced SCC of the lung whose tumors demonstrated FGFR1 amplification of > 5 copies by fluorescence in situ hybridization were enrolled.
|
27315356 |
2016 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Large-scale genomics have recently expanded the lung cancer landscape with FGFR1 amplification found in 10-20% of squamous cell carcinomas (SCCs).
|
26549034 |
2016 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
The combination of ATO/PD173074 was studied in a proof-of-principle model using a lung SCC cell line with FGFR1 overexpression: SK-MES-1.
|
27794399 |
2016 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study was designed to investigate the prevalence and clinical significance of FGFR1 amplification in a tissue microarray containing 346 adenocarcinomas and 254 squamous cell carcinomas of the esophagus, using dual-labeling fluorescence in situ hybridization (FISH) analysis.
|
26555375 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that FGFR1 amplification is associated with smoking history and squamous cell carcinoma histology and might indicate poor prognosis.
|
25086725 |
2014 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
One hundred twelve primary tumors (including squamous cell carcinoma [SCC], carcinoma associated with an inverted papilloma, sinonasal undifferentiated carcinoma [SNUC], adenocarcinoma, adenoid cystic carcinoma [ACC], esthesioneuroblastoma, and 9 corresponding lymph node metastases) were assessed by fluorescence in situ hybridization (FISH) for FGFR1 copy number status.
|
23913758 |
2014 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGFR1 amplification is common in early-stage SCC of the lung and is an independent and adverse prognostic marker.
|
24853178 |
2014 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGFR1 amplifications were found in a total of 30/175 (17%) brain metastases: 4/21 (19%) squamous cell carcinomas, 20/130 (15.3%) adenocarcinomas, 2/12 (16.6%) adenosquamous carcinomas, 4/9 (44.4%) large cell carcinomas and 0/3 neuroendocrine large cell carcinoma.
|
24183471 |
2014 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amplification of FGFR1 predominated in squamous cell carcinomas, although the association with overexpression was inconclusive.
|
23400671 |
2013 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Tissue microarrays containing 135 primary lung SqCCs and 58 matching lymph node metastases were tested by interphase fluorescence in situ hybridization for DNA copy number (CN) abnormalities at the 8p12 region including FGFR1.
|
24077455 |
2013 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
High FGFR1 gene copy number is a common finding in SCC and LCC and is an independent favourable prognostic factor.
|
23806793 |
2013 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome.
|
23434054 |
2013 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, within the squamous cell carcinomas the FGFR1 copy number status did not significantly correlate with gender, smoking status, pathological stages and differentiation status of the lung cancers.
|
22179561 |
2012 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGFR1 amplifications were observed in 20% of pulmonary squamous carcinomas but not in adenocarcinomas.
|
22684217 |
2012 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The higher FGFR1 gene copy numbers in SCC compared to ADC did not reach statistical significance.
|
22648708 |
2012 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Personalized therapy of lung cancer.
|
22286583 |
2012 |
|
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Archived tissue from NSCLC (adenocarcinoma and SCC; n = 321) and adjacent bronchial epithelial specimens (n = 426) were analyzed for the immunohistochemical expression of bFGF, FGFR1, and FGFR2, and the findings were correlated with clinicopathologic features of the patients.
|
18829480 |
2008 |
|
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Archived tissue from NSCLC (adenocarcinoma and SCC; n = 321) and adjacent bronchial epithelial specimens (n = 426) were analyzed for the immunohistochemical expression of bFGF, FGFR1, and FGFR2, and the findings were correlated with clinicopathologic features of the patients.
|
18829480 |
2008 |